Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial ID NCT00600587

PubWeight™ 44.88‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00600587

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 46.35
2 Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007 2.15
3 Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007 1.87
4 Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer 2007 1.03
5 Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol 2008 0.91
6 Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J Hematol Oncol 2015 0.87
7 Treatment of stage IIIA non-small cell lung cancer. Chest 2003 0.85
8 Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther 2014 0.80
Next 100